Biocytogen (HKG: 2315), a leading biopharmaceutical company based in China, has announced a strategic research collaboration and licensing agreement with the Netherlands-based SOTIO Biotech B.V. The partnership grants SOTIO an exclusive option to license multiple fully human bispecific antibodies generated through Biocytogen’s proprietary RenLite platform. These antibodies will be utilized by SOTIO to develop next-generation antibody-drug conjugates (ADCs) targeting solid tumors.
The RenLite platform, known for producing bispecific antibodies, has caught the attention of SOTIO, which aims to leverage this technology to create cutting-edge treatments for cancer. The agreement also encompasses an option for SOTIO to use Biocytogen’s ADC platform, further expanding the scope of potential therapies.
Under the terms of this agreement, Biocytogen stands to receive upfront payments, potential milestone payments reaching up to USD 325.5 million, and royalties based on net sales in the low single digits. The collaboration will see SOTIO and Biocytogen working closely during the research phase of the bispecific programs, with SOTIO taking the lead on nonclinical and clinical development, manufacturing, and commercialization of the ADC products.
This strategic partnership exemplifies the growing trend of global collaborations in the biopharmaceutical industry, aimed at developing innovative treatments for cancer. It also highlights the recognition of Chinese biopharmaceutical companies’ R&D capabilities on the international stage. As Biocytogen and SOTIO join forces, they aim to accelerate the discovery and delivery of novel therapies to patients in need, potentially transforming the treatment landscape for various types of solid tumors.- Flcube.com
